INTRODUCTION AND OBJECTIVES: Penis transplantation represents a new paradigm in restoring anatomic appearance, urine conduit, and sexual function following genitourinary tissue loss. Genitourinary injuries and diseases that result in partial or complete penile loss have devastating functional and emotional consequences for patients leading to significant mental health sequelae, including depression and suicide. To date, only two penis transplants have been performed worldwide. We describe the 6 month follow up of the first successful penis transplant in the United States in a patient with a history of subtotal penectomy for penile cancer.
METHODS: Following Institutional Review Board approval, extensive medical, surgical, and radiological evaluations of the patient were performed. His candidacy was reviewed by an multidisciplinary team of surgeons, physicians, psychiatrists, social workers, and nurse coordinators. After an appropriate donor was identified by United Network for Organ Donation, allograft procurement and recipient preparation took place concurrently. Anastomoses of the urethra, corpora, cavernosal and dorsal arteries, dorsal vein, and dorsal nerves were performed as well as inclusion of a donor skin pedicle as the composite allograft. Immunosuppression consisted of antithymocyte globulin induction, mycophenolate mofetil, and methylprednisolone, and tacrolimus.
RESULTS: Postoperatively, the allograft had an excellent capillary refill and strong Doppler signals. Operative interventions on postoperative days 2 and 13 were required for hematoma evacuation and debridement of maturing skin eschar. At 3 weeks, no anastomotic leaks were detected on peri-catheter urethrogram and the catheter was removed. The patient developed one episode of steroid-resistant rejection (Banff III) which required a repeat course of methylprednisolone and antithymocyte globulin. At 6 months, the patient has recovered partial sensation of the penile shaft and has spontaneous penile tumescence. Our patient reports increased overall health satisfaction, dramatic improvement of self-image, and optimism for the future.
CONCLUSIONS: We have shown that it is feasible to perform penile transplantation with excellent results. Furthermore, this experience demonstrates that penile transplantation can be successfully performed with conventional immunosuppression. We propose that our penile transplantation pilot experience with encouraging short-term results represents a proof of concept that establishes a new and emerging field in reconstructive transplantation.
Source of Funding: Massachusetts General Hospital

MP30-02 SURVIVAL OF KIDNEY TRANSPLANTS FROM UNCONTROLLED DCD DONORS UNDER NORMOTHERMIC PRESERVATION: ARE THEY AS GOOD AS DBD KIDNEYS?
F elix Guerrero Ramos*, Teresa Cavero Escribano, Angel Tejido S anchez, Alfredo Rodríguez Antolín, Manuel Pamplona Casamayor, Jos e Medina Polo, Federico de la Rosa Kehrmann, Jos e Manuel Duarte Ojeda, Felipe Villacampa Aub a, Amado Andr es Belmonte, Juan Passas Martínez, Madrid, Spain INTRODUCTION AND OBJECTIVES: Kidney transplantation is the best treatment for end-stage chronic kidney disease, with multiple advantages over dialysis. Because of the large quantity of people awaiting a kidney transplant there is an important organ shortage, which has led to investigate new sources of grafts. Donation after cardiac death (DCD) has emerged in the last two decades to increase the donor pool, classically composed by donation after brain death (DBD). Uncontrolled DCD is popular in not many countries, because of ethical issues among others; moreover, these kidneys have a higher ischemic risk due to longer cold ischemia time. In this series, we compare the survival of uncontrolled DCD transplants related to DBD transplants.
METHODS: We carried out a retrospective review of 300 kidney transplants (150 uncontrolled DCD with normothermic perfusion and 150 DBD) performed in our centre between 2007 and 2012 on recipients under 60 years old. We collected preoperative features, surgical technique, graft characteristics (cold ischemia time...) and postoperative events. We estimated crude survival and death-censored and primary non function-censored survival with Kaplan Meier curves, using Stata v12.0 for Windows.
RESULTS: Both groups were comparable regarding baseline characteristics, with a median follow-up of 53.6 months (interquartile range 35.3-70.5), and a median age of 43 years for donors and 46 for recipients. Crude survival (Figure 1 ) at 1, 5 and 10 years was 93.3%, 90.9% and 88.5% for DBD kidneys and 91.1%, 83.6% and 81.6% for uncontrolled DCD grafts, with no statistically significant difference (p¼0,100). Primary non function and death censored survival (Figure 2 ) at 1, 5 and 10 years was 95.6%, 93% and 88.7% for DBD grafts and 97%, 88.9% and 86.9% for DCD grafts.
CONCLUSIONS: Uncontrolled DCD kidneys under normothermic preservation have similar survival as DBD grafts. Hence, they can be considered as a valuable source to increase the donor pool so as to minimize the current organ shortage. Vol. 197, No. 4S, Supplement, Saturday, May 13, 2017 THE JOURNAL OF UROLOGY âINTRODUCTION AND OBJECTIVES: Kidney transplantation (KT) is the preferred treatment for patients with end-stage renal disease. In order to reduce the morbidity of the open surgery, a robotic assisted approach has been recently introduced. According to the literature, the robotic surgery allows the performance of KT under optimal operative conditions while maintaining the safety and the functional results of the open approach. We present the one-year results from the ERUS Robotic Kidney Transplantation Group common prospective recruitment database of Robotic assisted kidney transplantats (RAKT) on 69 cases.
METHODS: An ERUS RAKT group was created in July 2015 with the intent of generating prospective data on robotic kidney transplantation. A common prospective recruitment database of RAKT performed at 8 different European Centers was therefore created in July 2015. Functional and surgical data were analyzed and herein reported.
RESULTS: The patients demographic characteristics were as follows: 29 adult females and 40 males with mean age 42 years old (range: 25-64), mean BMI 26 kg/m2 (range: 22-33), and mean pretransplantation serum creatinine 484 umol/L (range: 98-919) with a mean GFR: 10.4 ml/min per 1.73 m2 (range: 3-29). There were no vascular and ureteral anomalies in the cases included. The mean ASA score were 2. Overall surgical time was 324 min (range: 220-430) with vascular suture time of 42 min (range: 32-48), and estimated blood loss < 80 ml. Overall ischemia time (including warm ischemia, cold ischemia and rewarming time) was 98.9 min (range: 84-140). The average rewarming time was 55 min (range 51-58). Two patients were converted to open transplantation. No major surgical intra-operative complications were observed. There were two cases (3%) of transplantectomy for a massive arterial thrombosis on POD 2. One case of intraperitoneal hematoma occurred on POD 1, and was successfully managed laparoscopically. The mean post-operative serum creatinine level was 204 umol/L (range: 81-479) on post-operative day (POD) 7. Post-operative pain, evaluated with Visual Analog Scale (VAS) score, was optimal. The mean hospital stay was 6 AE 1 days (range 4-8 days). The mean time of ureteral catheter was 15 days (range: 14-16) after the surgery. There were five cases (7%) of delayed graft function although at 1 month follow up. Furthermore, no arterial nor ureteral strictures occurred.
CONCLUSIONS: This is the first European study on RAKT. RAKT with regional hypothermia appears to be a safe and reproducible surgical procedure in a properly selected group of patient. The potential advantages of RAKT are related to the quality of the vascular anastomosis, the possible lower complication rate and the shorter recovery of the recipients. The success rate in this group is comparable to conventional open KT.
Source of Funding: none
MP30-04 INDUCTION OF DELAYED RENAL ALLOGRAFT TOLERANCE WITH CLINICAL AVAILABLE REAGENTS IN NON-HUMAN PRIMATES
Kiyohiko Hotta*, Tetsu Oura, Abbas Dehnadi, Gilles Benichou, A. Benedict Cosimi, Tatsuo Kawai, Boston, MA INTRODUCTION AND OBJECTIVES: We have previously reported successful induction of renal allograft tolerance following a period of conventional immunosuppression (Delayed tolerance) using a nonmyeloablative conditioning with anti-CD154 and anti-CD8 mAbs or LFA3-Ig in MHC-mismatched kidney transplantation (KTx). However, since these reagents are not currently clinically available, the protocol needs to be revised to apply this approach to clinical deceased donor transplantation. In this study, we tested clinically available reagents, CTLA4Ig(belatacept) and rabbit-ATG(Thymoglobulin), for induction of delayed tolerance.
METHODS: KTx was performed with a triple drug immunosuppression (I.S.) (tacrolimus, mycophenolate mofetil and predonisone) in MHC mismatched cynomolgus monkeys. Four months after KTx, recipients received donor bone marrow transplant (BMT) with a nonmyeloablative conditioning regimen that consisted of low dose TBI, thymic irradiation, belatacept, Thymoglobulin and a one month course of CyA.
RESULTS: The first monkey received the regimen with Thymoglobulin (20mg/kgÂ3) and belatacept (20mg/kg Â4). Although the recipient developed mixed chimerism (MC), he died due to lethal CMV on day 19 after BMT. Another recipient received a reduced dose of Thymoglobulin (10mg/kgÂ2) but increased dose of belatacept (20mg/kg Â6). The recipient developed MC but died due to lymphoma on day 49. All four recipients that received Thymoglobulin (10mg/kgÂ2) and belatacept (20mg/kg Â4) developed MC without infectious complications or lymphoma and 3/4 achieved long-term renal allograft survival without I.S. (>300 days). The last recipient in this group did not develop rejection but died on day 108 due to ischemic kidney injury caused by hypotension during the renal allograft biopsy.
CONCLUSIONS: Induction of delayed renal allograft tolerance is achieved in nonhuman primates by a nonmyeloablative conditioning with belatacept and Thymoglobulin. This protocol for delayed tolerance is directly applicable to clinical deceased donor kidney transplantation.
